Serum <scp>B</scp>‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez(Institute for Myeloma & Bone Cancer Research), James R. Berenson(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Alex Kitto(Institute for Myeloma & Bone Cancer Research), Austin Robinson(University of Virginia Health System), Cathy S. Wang(Institute for Myeloma & Bone Cancer Research), Cameryn P Ahles(Institute for Myeloma & Bone Cancer Research), Ori Yellin, Marissa P. Dreyer(Institute for Myeloma & Bone Cancer Research), Gabriel N. Waterman(Institute for Myeloma & Bone Cancer Research), Benjamin Bonavida(University of California, Los Angeles), Jennifer Li(Beth Israel Deaconess Medical Center), Cydney Nichols(Institute for Myeloma & Bone Cancer Research), Mingjie Li(Shenyang Pharmaceutical University), Haiming Chen(Guangzhou University of Chinese Medicine), Robert Vescio(Royal Adelaide Hospital), John Crowley(AbbVie (United States)), Dylan T. Kirk(Institute for Myeloma & Bone Cancer Research), Ralph V. Boccia(Center for Cancer and Blood Disorders), Erik Madden(University of California, Los Angeles)
Cited by 277
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721